Insmed Incorporated (NASDAQ:INSM - Get Free Report) COO Roger Adsett sold 1,860 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $71.50, for a total transaction of $132,990.00. Following the sale, the chief operating officer now directly owns 141,323 shares of the company's stock, valued at $10,104,594.50. This represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Roger Adsett also recently made the following trade(s):
- On Wednesday, May 14th, Roger Adsett sold 1,925 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total transaction of $126,299.25.
- On Tuesday, May 13th, Roger Adsett sold 7,482 shares of Insmed stock. The stock was sold at an average price of $67.81, for a total transaction of $507,354.42.
Insmed Stock Up 1.2%
NASDAQ:INSM traded up $0.88 during trading hours on Friday, reaching $73.62. The company's stock had a trading volume of 1,558,246 shares, compared to its average volume of 2,072,016. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company has a market cap of $13.41 billion, a price-to-earnings ratio of -13.17 and a beta of 0.80. Insmed Incorporated has a one year low of $56.03 and a one year high of $84.91. The business's 50-day moving average is $69.28 and its 200-day moving average is $73.03.
Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The company had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Insmed's quarterly revenue was up 22.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.06) EPS. Equities research analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.
Institutional Investors Weigh In On Insmed
Several institutional investors and hedge funds have recently added to or reduced their stakes in INSM. Cullen Frost Bankers Inc. grew its holdings in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 221 shares during the last quarter. Elequin Capital LP acquired a new position in Insmed in the 4th quarter valued at $28,000. Steward Partners Investment Advisory LLC raised its holdings in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 163 shares during the period. NBC Securities Inc. acquired a new position in Insmed during the 1st quarter worth $49,000. Finally, V Square Quantitative Management LLC lifted its position in Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 248 shares during the last quarter.
Analyst Ratings Changes
INSM has been the subject of a number of research analyst reports. Wells Fargo & Company increased their target price on Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a report on Wednesday, February 19th. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a research note on Wednesday, February 19th. Jefferies Financial Group initiated coverage on Insmed in a research note on Tuesday, May 13th. They set a "buy" rating and a $105.00 target price on the stock. Guggenheim reiterated a "buy" rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. Finally, Bank of America increased their price target on shares of Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, Insmed currently has an average rating of "Moderate Buy" and a consensus price target of $97.79.
View Our Latest Analysis on Insmed
About Insmed
(
Get Free Report)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
See Also
Before you consider Insmed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.
While Insmed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
